Global pharmaceutical company Bristol Myers Squibb is teed up to acquire Turning Point Therapeutics for $76 per share by the end of the third quarter.
Read the full post on Becker's Hospital Review - Healthcare News
Bristol Myers Squibb to buy Turning Point Therapeutics for $4.1B
